Access for Chemists (Compound Providers) - Overview

As a chemist you are invited to include your compounds into the jointly used EU-OPENSCREEN compound collection, which is screened against a wide range of biological assays, thereby delivering extensive information about the biological activities of your compounds.

EU-OPENSCREEN bioprofiles your submitted compounds in a set of standard assays to identify basic biological activities (e.g. cell morphology and growth). Thus, you will rapidly receive data on the biological activities of your submitted compounds. In addition, you will continuously receive screening data. This opens the perspective that some of your compounds will be identified as hits. In that case you will be asked to be involved in the following research projects and novel collaborations with assay providers from all over Europe and beyond.

Please contact us at compound-submission@eu-openscreen.eu if you are interested to include your compound into our collection.

Chemists have the possibility to add their compounds to the EU-OPENSCREEN compound collection as part of the “academic compounds”.

It would be beneficial if compounds were provided with proof of identity (either Mass or Nuclear magnetic resonance NMR) and purity. The structure of each compound will undergo computational filters to assess chemical-physico properties (i.e. solubility, molecular weight), reactivity and diversity. The complete explanation of the physico-chemical properties assessment can be found here.

If non-compliant with the desired standards the compound will be still accepted as part of the library, but will be “flagged” in order to raise awareness and allow for a rational interpretation of hit compounds.

The compound will then be bioprofiled, an empirical characterization and annotation for basic physico-chemical and “essential to know” biological properties. All results will be part of the European Chemical Biology Database, although for the first six months in the non-public disclosed part of the database.

Submitted compounds are then screened at EU-OPENSCREEN screening partner sites in scientific projects.

If a compound is regarded, in any of the assays as a hit, the chemist will be promptly informed and a collaboration between assay provider and chemist for further research projects or generation of intellectual property rights may start.

Both parties can ask for an embargo period; if this is not considered, all results will be part of the European Chemical Biology Database (ECBD).